Bristol Myers moves SC to stop Zydus from selling biosimilar cancer drug

US firm Bristol Myers Squibb is in the Supreme Court seeking to halt Zydus Lifesciences from manufacturing and selling a biosimilar cancer drug. The court will hear the appeal on February 4. BMS markets the drug nivolumab under brands Opdivo and Opdyta.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/muyts60
via IFTTT